LEGN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 20129 min ago

@ $52.08

Išleistas: 15 bal. 2024 @ 21:17

Grąža: -12.34%

Ankstesnis signalas: bal. 15 - 20:41

Ankstesnis signalas: Pardavimas

Grąža: -1.02 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 20:46):

Stats
Šios dienos apimtis	542 000
Vidutinė apimtis	974 846
Rinkos kapitalizacija	8.30B
EPS	$0 ( 2024-03-11 )
Kita pelno data	( $-0.240 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.53
ATR14	$0.0340 (0.07%)

Tūris Koreliacija

Ilgas: 0.00 (neutral)

Trumpas: -0.95 (very strong negative)

Signal:(24.881) Possible Trading Opportunity Present (swing)

Legend Biotech Corp Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
AQST	0.804

10 Labiausiai neigiamai susiję koreliacijos
MACQU	-0.813
CFACU	-0.811

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Legend Biotech Corp Koreliacija - Valiuta/Žaliavos

-0.43
( neutral )

-0.08
( neutral )

0.00
( neutral )

-0.77
( moderate negative )

0.75
( moderate )

0.52
( weak )

Legend Biotech Corp Finansinės ataskaitos

Annual	2023
Pajamos:	$285.14M
Bruto pelnas:	$120.48M (42.25 %)
EPS:	$-2.94

FY	2023
Pajamos:	$285.14M
Bruto pelnas:	$120.48M (42.25 %)
EPS:	$-2.94

FY	2022
Pajamos:	$117.01M
Bruto pelnas:	$51.64M (44.14 %)
EPS:	$-2.81

FY	2021
Pajamos:	$89.79M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.74

Financial Reports:

No articles found.

Legend Biotech Corp

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.